Ann Lab Med.  2024 Jan;44(1):92-96. 10.3343/alm.2024.44.1.92.

In Vitro Activity of Benzimidazole (SPR719) Against Clinical Isolates of Nontuberculous Mycobacteria With and Without Clarithromycin or Amikacin Resistance

• Kim DH
• Zo S
• Kim SY
• Jhun BW

• KMID: 2550227
• DOI: http://doi.org/10.3343/alm.2024.44.1.92

Abstract

Limited data are available regarding the in vitro activity of SPR719, a derivative of benzimidazole, against diverse nontuberculous mycobacteria (NTM) species. We investigated the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of SPR719 against clinical NTM isolates, including clarithromycin- and amikacin-resistant strains. NTM isolates were obtained from patients with NTM-pulmonary disease caused by various NTM species, including Mycobacterium avium complex, M. abscessus (subspecies abscessus and massiliense), M. kansasii, and M. fortuitum. Regardless of clarithromycin or amikacin resistance, the MIC and MBC values of SPR719 were comparable among these major pathogenic NTM species. In over 70% of the isolates, the MIC values were ≤ 2 µg/mL with MBC values of ≤ 4 µg/mL. The MIC and MBC values of M. kansasii were relatively lower than those of the other species with little difference between them, demonstrating the bactericidal properties of SPR719. The in vitro activity of SPR719 against major clinical NTM species suggests that SPR719 can serve as a novel treatment option for NTM-pulmonary disease.

Keyword

Amikacin; Anti-bacterial agents; Benzimidazoles; Clarithromycin; Lung diseases; Microbial sensitivity tests

Reference

1. Prevots DR, Marras TK. 2015; Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 36:13–34. DOI: 10.1016/j.ccm.2014.10.002. PMID: 25676516. PMCID: PMC4332564.

2. Stout JE, Koh WJ, Yew WW. 2016; Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis. 45:123–34. DOI: 10.1016/j.ijid.2016.03.006. PMID: 26976549.

3. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. 2012; Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 185:881–6. DOI: 10.1164/rccm.201111-2016OC. PMID: 22312016. PMCID: PMC3360574.

4. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. 2017; British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 72(S2):ii1–ii64. DOI: 10.1136/thoraxjnl-2017-210927. PMID: 29054853.

5. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, et al. 2020; Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis. 71:e1–e36. DOI: 10.1093/cid/ciaa241. PMID: 32628747. PMCID: PMC7768748.

6. Keri RS, Rajappa CK, Patil SA, Nagaraja BM. 2016; Benzimidazole-core as an antimycobacterial agent. Pharmacol Rep. 68:1254–65. DOI: 10.1016/j.pharep.2016.08.002. PMID: 27686965.

7. Gong Y, Somersan Karakaya S, Guo X, Zheng P, Gold B, Ma Y, et al. 2014; Benzimidazole-based compounds kill Mycobacterium tuberculosis. Eur J Med Chem. 75:336–53. DOI: 10.1016/j.ejmech.2014.01.039. PMID: 24556148.

8. Yoon YK, Ali MA, Wei AC, Choon TS, Ismail R. 2015; Synthesis and evaluation of antimycobacterial activity of new benzimidazole aminoesters. Eur J Med Chem. 93:614–24. DOI: 10.1016/j.ejmech.2013.06.025. PMID: 24996257.

9. Aragaw WW, Cotroneo N, Stokes S, Pucci M, Critchley I, Gengenbacher M, et al. 2022; In vitro resistance against DNA gyrase inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus. Microbiol Spectr. 10:e0132121. DOI: 10.1128/spectrum.01321-21. PMID: 35019671. PMCID: PMC8754139.

10. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. 2012; Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother. 67:810–8. DOI: 10.1093/jac/dkr578. PMID: 22290346.

11. Moon SM, Park HY, Kim SY, Jhun BW, Lee H, Jeon K, et al. 2016; Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 60:6758–65. DOI: 10.1128/AAC.01240-16. PMID: 27572413. PMCID: PMC5075083.

12. Choi H, Kim SY, Kim DH, Huh HJ, Ki CS, Lee NY, et al. 2017; Clinical characteristics and treatment outcomes of patients with acquired macrolide-resistant Mycobacterium abscessus lung disease. Antimicrob Agents Chemother. 61:e01146. DOI: 10.1128/AAC.01146-17. PMID: 28739795. PMCID: PMC5610486.

13. Choi H, Kim SY, Lee H, Jhun BW, Park HY, Jeon K, et al. 2017; Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium massiliense lung disease. Antimicrob Agents Chemother. 61:e02189. DOI: 10.1128/AAC.02189-16. PMID: 27872066. PMCID: PMC5278753.

14. Jhun BW, Yang B, Moon SM, Lee H, Park HY, Jeon K, et al. 2018; Amikacin inhalation as salvage therapy for refractory nontuberculous mycobacterial lung disease. Antimicrob Agents Chemother. 62:e00011–18. DOI: 10.1128/AAC.00011-18. PMID: 29661870. PMCID: PMC6021683.

15. Huh HJ, Kim SY, Shim HJ, Kim DH, Yoo IY, Kang OK, et al. 2019; GenoType NTM-DR performance evaluation for identification of Mycobacterium avium complex and Mycobacterium abscessus and determination of clarithromycin and amikacin resistance. J Clin Microbiol. 57:e00516–19. DOI: 10.1128/JCM.00516-19. PMID: 31167842. PMCID: PMC6663903.

16. CLSI. 2018. Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes; approved standard. 3rd ed. CLSI M24. Clinical and Laboratory Standards Institute;Wayne, PA:

17. CLSI. 2018. Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes; approved standard. 1st ed. CLSI M62. Clinical and Laboratory Standards Institute;Wayne, PA:

18. Pennings LJ, Ruth MM, Wertheim HFL, van Ingen J. 2021; The benzimidazole SPR719 shows promising concentration-dependent activity and synergy against nontuberculous mycobacteria. Antimicrob Agents Chemother. 65:e02469–20. DOI: 10.1128/AAC.02469-20. PMID: 33468478. PMCID: PMC8097464.

19. Pidot SJ, Porter JL, Lister T, Stinear TP. 2021; In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera. PLoS Negl Trop Dis. 15:e0009636. DOI: 10.1371/journal.pntd.0009636. PMID: 34310615. PMCID: PMC8341698.

20. Talley AK, Thurston A, Moore G, Gupta VK, Satterfield M, Manyak E, et al. 2021; First-in-human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections. Antimicrob Agents Chemother. 65:e0120821. DOI: 10.1128/AAC.01208-21. PMID: 34491803. PMCID: PMC8525492.